Targeted Animal Health MBF Therapeutics focuses on immunotherapeutic DNA vaccines for animal health with emphasis on high-impact swine diseases like PRRS and ASF, signaling a clear sales opportunity for partnerships with pig producers, swine vaccine distributors, and agricultural co-ops seeking safer, more effective respiratory disease vaccines.

Cross-Species Potential Although primarily serving animal health, MBF notes translational opportunities in human health, suggesting potential co-development or licensing discussions with biotech and pharma firms pursuing next-generation DNA vaccine platforms and immunotherapy applications beyond veterinary use.

DNA Vaccine Platform The T-Max plasmid DNA vaccine platform offers cross-protective antigen selection, non-antibiotic plasmids, immunomodulators, and CaptaVa, which positions MBF to engage with partners seeking innovative vaccine delivery systems and durable T cell–mediated immunity for novel or tough-to-treat pathogens.

Strategic Partnerships Historical hiring of board members with AI and big data experience, plus collaborations like with MRIGlobal, indicates MBF is open to co-development and strategic alliances; sales opportunities exist in joint ventures, licensing, or research collaborations to accelerate vaccine development.

Regulatory and Market Readiness With focus on economically significant diseases and a platform designed to improve safety and efficacy over KWV and MLV vaccines, MBF may attract funding and partnership discussions with livestock producers, regulators, and industry groups aiming to mitigate trade losses from ASF and PRRS through safer vaccines.